Remember the treatment was measured on a 100 day survival where 64% of patients responded to treatment, meaning 36% did not. Of that 64%, 100 day survival was 81% with the non responder survival rate at 39%.
Bringing these 2 percentages together gets a 51.8% (0.64*0.81) chance of survival to day 100 when using Prochymal... that's really not that great especially when compared to the non-responder 100 day survival at 39%.
So all up, this treatment provides an additional 12.8% chance of surviving to day 100.... and that costs US $113 000 to $170 000.
With minimal side effects it comes down to cost. Do you think people are willing to pay that much for a 12.8% chance? I think some people will.... but will the majority of the market pay it, maybe, maybe not it will depend on subsidies.
This is a simplified scenario in the fact that I have not accounted for grade of disease (B, C, D), you can do your own math for each grade. Someone please check my logic, I think it is sound. If you can prove otherwise, then good on you.
- Forums
- ASX - By Stock
- Revenue from Japan
Remember the treatment was measured on a 100 day survival where...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 86854 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.965 |
1 | 23000 | 0.960 |
8 | 163220 | 0.955 |
8 | 87646 | 0.950 |
3 | 82684 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 86854 | 7 |
0.975 | 37184 | 2 |
0.980 | 44810 | 6 |
0.985 | 88504 | 4 |
0.990 | 54328 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online